Plumbagin Triggers Cuproptosis in Hepatocellular Carcinoma (HCC) via the DNA-Methyltransferase 1 (DNMT1)/microRNA-302a-3p (miR-302a-3p)/ATPase Copper Transporting Beta (ATP7B) Axis

Abstract

Induction of cuproptosis in tumor cells is an emerging direction for cancer drug development. Plumbagin (PLB), a natural biological molecule, has anticancer activities, partially via copper-dependent mechanisms. But it remains unclear if PLB can induce cuproptosis in hepatocellular carcinoma (HCC). In this study, PLB showed HCC-suppressive activities and caused representative molecular phenotypes of cuproptosis, whereas tetrathiomolybdate, an inhibitor of cuproptosis, could alleviate these effects the most. The mRNA and protein expression levels of the primary hepatic copper exporter, ATPase copper transporting beta (ATP7B), decreased in PLB-treated HCC cells, which might cause the accumulation of intracellular copper and trigger cuproptosis. An upstream ATP7B-regulatory microRNA, microRNA-302a-3p (miR-302a-3p), was identified by quantification and validated by the overexpression/inhibition experiment and luciferase reporter assay. Moreover, PLB was found to reduce the protein level of DNA-methyltransferase 1 (DNMT1), thereby enhancing the promoter hypomethylation and the expression of miR-302a-3p. Gene manipulation experiments further demonstrated that ATP7B, miR-302a-3p, and DNMT1 mediated PLB-induced cuproptosis. Preliminary clinical analyses showed that low ATP7B expression levels were associated with better prognosis, supporting the importance of ATP7B-lowering therapeutic strategies in HCC. Together, our results indicate that PLB triggers HCC cuproptosis via the DNMT1/miR-302a-3p/ATP7B axis, providing a potential therapeutic strategy for HCC.

Keywords

ATPase copper transporting beta (ATP7B) / cuproptosis / DNA-methyltransferase 1 (DNMT1) / hepatocellular carcinoma (HCC) / plumbagin (PLB)

References

[1] J. M. Llovet, R. K. Kelley, A. Villanueva, et al., “Hepatocellular Carcinoma,” Nature reviews Disease Primers 7, no. 1 (2021): 6.

[2] H. Rumgay, M. Arnold, J. Ferlay, et al., “Global Burden of Primary Liver Cancer in 2020 and Predictions to 2040,” Journal of Hepatology 77, no. 6 (2022): 1598-1606.

[3] J. D. Gordan, E. B. Kennedy, G. K. Abou-Alfa, et al., “Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update,” Journal of Clinical Oncology 42, no. 15 (2024): 1830-1850.

[4] A. G. Singal, F. Kanwal, and J. M. Llovet, “Global Trends in Hepatocellular Carcinoma Epidemiology: Implications for Screening, Prevention and Therapy,” Nature Reviews Clinical Oncology 20, no. 12 (2023): 864-884.

[5] V. Chew, C. H. Chuang, and C. Hsu, “Translational Research on Drug Development and Biomarker Discovery for Hepatocellular Carcinoma,” Journal of Biomedical Science 31, no. 1 (2024): 22.

[6] D. Xie, J. Shi, J. Zhou, J. Fan, and Q. Gao, “Clinical Practice Guidelines and Real-Life Practice in Hepatocellular Carcinoma: A Chinese Perspective,” Clinical and Molecular Hepatology 29, no. 2 (2023): 206-216.

[7] K. Wang, Y. J. Xiang, H. M. Yu, et al., “Adjuvant Sintilimab in Resected High-Risk Hepatocellular Carcinoma: A Randomized, Controlled, Phase 2 Trial,” Nature Medicine 30, no. 3 (2024): 708-715.

[8] A. Galmiche, B. Chauffert, and J. C. Barbare, “New Biological Perspectives for the Improvement of the Efficacy of Sorafenib in Hepatocellular Carcinoma,” Cancer Letters 346, no. 2 (2014): 159-162.

[9] L. Zhang, X. M. Li, X. H. Shi, et al., “Sorafenib Triggers Ferroptosis via Inhibition of HBXIP/SCD Axis in Hepatocellular Carcinoma,” Acta Pharmacologica Sinica 44, no. 3 (2023): 622-634.

[10] B. L. Adamsen, K. L. Kravik, and P. M. De Angelis, “DNA Damage Signaling in Response to 5-fluorouracil in Three Colorectal Cancer Cell Lines With Different Mismatch Repair and TP53 Status,” International Journal of Oncology 39, no. 3 (2011): 673-682.

[11] Y. Sun, L. Wu, Y. Zhong, et al., “Single-cell Landscape of the Ecosystem in Early-Relapse Hepatocellular Carcinoma,” Cell 184, no. 2 (2021): 404-421.

[12] P. Tsvetkov, S. Coy, B. Petrova, et al., “Copper Induces Cell Death by Targeting Lipoylated TCA Cycle Proteins,” Science 375, no. 6586 (2022): 1254-1261.

[13] Y. Wang, L. Zhang, and F. Zhou, “Cuproptosis: A New Form of Programmed Cell Death,” Cellular and Molecular Immunology 19, no. 8 (2022): 867-868.

[14] C. Zhang, T. Huang, and L. Li, “Targeting Cuproptosis for Cancer Therapy: Mechanistic Insights and Clinical Perspectives,” Journal of Hematology & Oncology 17, no. 1 (2024): 68.

[15] Y. Yang, J. Wu, L. Wang, G. Ji, and Y. Dang, “Copper Homeostasis and Cuproptosis in Health and Disease,” MedComm 5, no. 10 (2024): e724.

[16] P. Zheng, C. Zhou, L. Lu, B. Liu, and Y. Ding, “Elesclomol: A Copper Ionophore Targeting Mitochondrial Metabolism for Cancer Therapy,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 271.

[17] W. Yang, Y. Wang, Y. Huang, et al., “4-Octyl Itaconate Inhibits Aerobic Glycolysis by Targeting GAPDH to Promote Cuproptosis in Colorectal Cancer,” Biomedicine & Pharmacotherapy 159 (2023): 114301.

[18] Z. Yang, Z. Zhao, H. Cheng, Y. Shen, A. Xie, and M. Zhu, “In-Situ Fabrication of Novel Au Nanoclusters-Cu(2+)@Sodium Alginate/Hyaluronic Acid Nanohybrid Gels for Cuproptosis Enhanced Photothermal/Photodynamic/Chemodynamic Therapy via Tumor Microenvironment Regulation,” Journal of Colloid & Interface Science 641 (2023): 215-228.

[19] C. Kiruthiga, K. P. Devi, S. M. Nabavi, and A. Bishayee, “Autophagy: A Potential Therapeutic Target of Polyphenols in Hepatocellular Carcinoma,” Cancers (Basel) 12, no. 3 (2020): 562.

[20] Q. Huang, H. Chen, Y. Ren, et al., “Anti-Hepatocellular Carcinoma Activity and Mechanism of Chemopreventive Compounds: Ursolic Acid Derivatives,” Pharmaceutical Biology 54, no. 12 (2016): 3189-3196.

[21] W. Chen, W. Yang, C. Zhang, et al., “Modulation of the p38 MAPK Pathway by Anisomycin Promotes Ferroptosis of Hepatocellular Carcinoma Through Phosphorylation of H3S10,” Oxidative Medicine and Cellular Longevity 2022 (2022): 6986445.

[22] R. Huo, W.-J. Yang, Y. Liu, et al., “Stigmasterol: Remodeling Gut Microbiota and Suppressing Tumor Growth Through Treg and CD8+ T Cells in Hepatocellular Carcinoma,” Phytomedicine 129 (2023): 155225.

[23] S. Han, S. Bi, T. Guo, et al., “Nano Co-Delivery of Plumbagin and Dihydrotanshinone I Reverses Immunosuppressive TME of Liver Cancer,” Journal of Controlled Release 348 (2022): 250-263.

[24] L. Yao, D. Yan, B. Jiang, et al., “Plumbagin Is a Novel GPX4 Protein Degrader That Induces Apoptosis in Hepatocellular Carcinoma Cells,” Free Radical Biology and Medicine 203 (2023): 1-10.

[25] Y. Lin, Y. Chen, S. Wang, et al., “Plumbagin Induces Autophagy and Apoptosis of SMMC-7721 Cells in Vitro and in Vivo,” Journal of Cellular Biochemistry 120, no. 6 (2019): 9820-9830.

[26] S. Nazeem, A. S. Azmi, S. Hanif, et al., “Plumbagin Induces Cell Death Through a Copper-Redox Cycle Mechanism in Human Cancer Cells,” Mutagenesis 24, no. 5 (2009): 413-418.

[27] S. Mukherjee, A. V. Sawant, S. S. Prassanawar, and D. Panda, “Copper-Plumbagin Complex Produces Potent Anticancer Effects by Depolymerizing Microtubules and Inducing Reactive Oxygen Species and DNA Damage,” ACS Omega 8, no. 3 (2023): 3221-3235.

[28] V. Davalos and M. Esteller, “Cancer Epigenetics in Clinical Practice,” CA: A Cancer Journal for Clinicians 73, no. 4 (2023): 376-424.

[29] D. M. Pereira, P. M. Rodrigues, P. M. Borralho, and C. M. Rodrigues, “Delivering the Promise of miRNA Cancer Therapeutics,” Drug Discovery Today 18, no. 5-6 (2013): 282-289.

[30] N. N. Zhao, X. Zhang, X. Zou, Y. Zhang, and C. Y. Zhang, “Controllable Assembly of Dendritic DNA Nanostructures for Ultrasensitive Detection of METTL3-METTL14 M(6)A Methyltransferase Activity in Cancer Cells and Human Breast Tissues,” Biosensors & Bioelectronics 228 (2023): 115217.

[31] L. Chen, J. Min, and F. Wang, “Copper Homeostasis and Cuproptosis in Health and Disease,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 378.

[32] Q. Xue, R. Kang, D. J. Klionsky, D. Tang, J. Liu, and X. Chen, “Copper Metabolism in Cell Death and Autophagy,” Autophagy 19, no. 8 (2023): 2175-2195.

[33] J. Xie, Y. Yang, Y. Gao, and J. He, “Cuproptosis: Mechanisms and Links With Cancers,” Molecular Cancer 22, no. 1 (2023): 46.

[34] Z. Zhang, X. Zeng, Y. Wu, Y. Liu, X. Zhang, and Z. Song, “Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma,” Frontiers in Immunology 13 (2022): 925618.

[35] S. Chen, P. Liu, L. Zhao, et al., “A Novel Cuproptosis-related Prognostic lncRNA Signature for Predicting Immune and Drug Therapy Response in Hepatocellular Carcinoma,” Frontiers in Immunology 13 (2022): 954653.

[36] D. Li, Z. Shi, X. Liu, et al., “Identification and Development of a Novel Risk Model Based on Cuproptosis-associated RNA Methylation Regulators for Predicting Prognosis and Characterizing Immune Status in Hepatocellular Carcinoma,” Hepatology International 17, no. 1 (2023): 112-130.

[37] B. Quan, W. Liu, F. Yao, et al., “LINC02362/hsa-miR-18a-5p/FDX1 Axis Suppresses Proliferation and Drives Cuproptosis and Oxaliplatin Sensitivity of Hepatocellular Carcinoma,” American Journal of Cancer Research 13, no. 11 (2023): 5590-5609.

[38] T. Xing, L. Li, Y. Chen, et al., “Targeting the TCA Cycle Through Cuproptosis Confers Synthetic Lethality on ARID1A-Deficient Hepatocellular Carcinoma,” Cell Reports Medicine 4, no. 11 (2023): 101264.

[39] P. Zhang, C. Zhou, X. Ren, et al., “Inhibiting the Compensatory Elevation of xCT Collaborates With Disulfiram/Copper-induced GSH Consumption for Cascade Ferroptosis and Cuproptosis,” Redox Biology 69 (2024): 103007.

[40] F. Yang, L. Jia, H. C. Zhou, et al., “Deep Learning Enables the Discovery of a Novel Cuproptosis-Inducing Molecule for the Inhibition of Hepatocellular Carcinoma,” Acta Pharmacologica Sinica 45, no. 2 (2024): 391-404.

[41] C. H. Yu, N. V. Dolgova, and O. Y. Dmitriev, “Dynamics of the Metal Binding Domains and Regulation of the Human Copper Transporters ATP7B and ATP7A,” IUBMB Life 69, no. 4 (2017): 226-235.

[42] W. C. J. Singleton, K. T. McInnes, M. A. Cater, et al., “Role of Glutaredoxin1 and Glutathione in Regulating the Activity of the Copper-Transporting P-Type ATPases, ATP7A and ATP7B,” Journal of Biological Chemistry 285, no. 35 (2010): 27111-27121.

[43] P. V. van den Berghe and L. W. Klomp, “Posttranslational Regulation of Copper Transporters,” Journal of Biological Inorganic Chemistry 15, no. 1 (2010): 37-46.

[44] D. Theile, S. Grebhardt, W. E. Haefeli, and J. Weiss, “Involvement of Drug Transporters in the Synergistic Action of FOLFOX Combination Chemotherapy,” Biochemical Pharmacology 78, no. 11 (2009): 1366-1373.

[45] A. Stalke, E. D. Pfister, U. Baumann, et al., “MTF1 binds to Metal-Responsive Element E Within the ATP7B Promoter and Is a Strong Candidate in Regulating the ATP7B Expression,” Annals of Human Genetics 84, no. 2 (2020): 195-200.

[46] J. Li, Y. Li, X. Sun, et al., “Silencing lncRNA-DARS-AS1 Suppresses Nonsmall Cell Lung Cancer Progression by Stimulating miR-302a-3p to Inhibit ACAT1 Expression,” Molecular Carcinogenesis 63, no. 4 (2024): 757-771.

[47] Y. Ye, Y. Song, J. Zhuang, et al., “MicroRNA-302a-3p Suppresses Hepatocellular Carcinoma Progression by Inhibiting Proliferation and Invasion,” OncoTargets and Therapy 11 (2018): 8175-8184.

[48] X. Pan, D. Li, J. Huo, F. Kong, H. Yang, and X. Ma, “LINC01016 Promotes the Malignant Phenotype of Endometrial Cancer Cells by Regulating the miR-302a-3p/miR-3130-3p/NFYA/SATB1 Axis,” Cell Death & Disease 9, no. 3 (2018): 303.

[49] L. Wu, Y. Wang, Q. Liu, et al., “Circ_0001665 Contributes to the Occurrence of Vestibular Schwannoma via Targeting miR-302a-3p/Adam9/EGFR Signaling Pathway,” Neuroscience 490 (2022): 206-215.

[50] Z. Wenfu, L. Bin, R. Binchan, et al., “DNA Methylation-mediated Repression of microRNA-410 Promotes the Growth of Human Glioma Cells and Triggers Cell Apoptosis Through Its Interaction With STAT3,” Scientific Reports 14, no. 1 (2024): 1556.

[51] J. K. Kim, J. H. Noh, K. H. Jung, et al., “Sirtuin7 Oncogenic Potential in Human Hepatocellular Carcinoma and Its Regulation by the Tumor Suppressors MiR-125a-5p and MiR-125b,” Hepatology 57, no. 3 (2013): 1055-1067.

[52] R. Yuan, Q. Zhi, H. Zhao, et al., “Upregulated Expression of miR-106a by DNA Hypomethylation Plays an Oncogenic Role in Hepatocellular Carcinoma,” Tumour Biology 36, no. 4 (2015): 3093-3100.

[53] Y. Zhe, L. Jiong, F. Guoxing, et al., “Hepatitis B Virus X Protein Enhances Hepatocarcinogenesis by Depressing the Targeting of NUSAP1 mRNA by miR-18b,” Cancer Biology & Medicine 16, no. 2 (2019): 276-287.

[54] Y. Saito, Y. Kanai, M. Sakamoto, H. Saito, H. Ishii, and S. Hirohashi, “Expression of mRNA for DNA Methyltransferases and Methyl-CpG-binding Proteins and DNA Methylation Status on CpG Islands and Pericentromeric Satellite Regions During Human Hepatocarcinogenesis,” Hepatology 33, no. 3 (2001): 561-568.

[55] C. H. Lin, S. Y. Hsieh, I. S. Sheen, et al., “Genome-wide Hypomethylation in Hepatocellular Carcinogenesis,” Cancer Research 61, no. 10 (2001): 4238-4243.

[56] Y. Saito, Y. Kanai, T. Nakagawa, et al., “Increased Protein Expression of DNA Methyltransferase (DNMT) 1 Is Significantly Correlated With the Malignant Potential and Poor Prognosis of Human Hepatocellular Carcinomas,” International Journal of Cancer 105, no. 4 (2003): 527-532.

[57] J. O. Lee, H. J. Kwun, J. K. Jung, K. H. Choi, D. S. Min, and K. L. Jang, “Hepatitis B Virus X Protein Represses E-Cadherin Expression via Activation of DNA Methyltransferase 1,” Oncogene 24, no. 44 (2005): 6617-6625.

[58] J. K. Jung, P. Arora, J. S. Pagano, and K. L. Jang, “Expression of DNA Methyltransferase 1 Is Activated by Hepatitis B Virus X Protein via a Regulatory Circuit Involving the p16INK4a-Cyclin D1-CDK 4/6-pRb-E2F1 Pathway,” Cancer Research 67, no. 12 (2007): 5771-5778.

[59] C. R. Xie, H. Sun, F. Q. Wang, et al., “Integrated Analysis of Gene Expression and DNA Methylation Changes Induced by Hepatocyte Growth Factor in Human Hepatocytes,” Molecular Medicine Reports 12, no. 3 (2015): 4250-4258.

[60] S. Venturelli, A. Berger, T. Weiland, et al., “Differential Induction of Apoptosis and Senescence by the DNA Methyltransferase Inhibitors 5-azacytidine and 5-aza-2'-Deoxycytidine in Solid Tumor Cells,” Molecular Cancer Therapeutics 12, no. 10 (2013): 2226-2236.

[61] C. Jiang and F. Gong, “DNA Methyltransferase 1: A Potential Gene Therapy Target for Hepatocellular Carcinoma?,” Oncology Research and Treatment 39, no. 7-8 (2016): 448-452.

[62] M. Barcena-Varela, S. Caruso, S. Llerena, et al., “Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma,” Hepatology 69, no. 2 (2019): 587-603.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.